Visual acuity stayed normal for most patients, but the optic nerve often did not
In intracranial hypertension following cerebral venous sinus thrombosis (CVT), the bedside exam can look deceptively reassuring. Visual acuity remained normal in 84.2% of the 19 adults studied, yet more sensitive neuro-ophthalmic testing told a different story: 26.3% had severe visual field loss and 15.8% showed thinning of the global peripapillary retinal nerve fiber layer on optical coherence tomography. A patient can read the chart and still be losing peripheral vision. That gap is clinically important, because visual acuity alone can miss ongoing optic nerve injury until the damage is already established.
This retrospective cohort included consecutive adults seen at a single tertiary intracranial hypertension clinic between 2019 and 2025. Mean age was 33.4 ± 12.1 years, and 11 of the 19 patients were female. Follow-up extended a mean of 3.4 ± 2.4 years after the diagnosis of CVT-related intracranial hypertension, which gives the cohort enough time to expose the chronicity of both visual and headache sequelae rather than only the acute venous event.
Peripheral field loss emerged as the more sensitive marker of injury
The study design matters because it used objective neuro-ophthalmic measures rather than relying on symptoms alone. Best-corrected visual acuity, automated perimetry, and optical coherence tomography were each used to assess the optic pathway. In a disease driven by raised intracranial pressure, papilledema and axonal stress may spare central acuity long before they spare the visual field. Automated perimetry is the tool that catches that earlier injury, and the cohort illustrates why it should not be reserved for patients who already complain of obvious visual decline.
Transverse sinus involvement was present in 78.9% of cases, and complete or near-complete recanalization occurred in 68.4%. Even with that degree of venous recovery, meaningful neuro-ophthalmic impairment persisted in a substantial minority. Venous recanalization can relieve one part of the pathophysiology, but it does not guarantee that the optic nerve has escaped chronic pressure-related stress. Once retinal ganglion cell axons are lost, recovery is limited; the structural thinning seen on optical coherence tomography is the residue of that injury.
Headache rarely disappeared, and medication overuse was common
The headache burden was striking. Headache persisted in 94.7% of patients, and the most common phenotype was tension-type headache, seen in 63.2%. In a disorder that often begins with intracranial pressure elevation, persistent headache can outlast the thrombosis itself and settle into a chronic pain pattern that is no longer explained solely by the original venous event. Raised pressure may initiate the syndrome, but repeated nociceptive signaling, central sensitization, and medication exposure can keep headache active long after recanalization.
Medication overuse headache was present in 26.3% of the cohort. That figure is clinically consequential because frequent analgesic use can blur the boundary between residual intracranial hypertension symptoms and a superimposed headache disorder. In practice, that means headache after CVT cannot be dismissed as “just recovery,” and it also cannot automatically be attributed to persistent venous obstruction. The management question becomes both neurologic and behavioral: is pressure still high, or has the headache phenotype shifted into a treatable overuse pattern?
The persistence of headache also raises a practical bedside issue. Patients may feel ill despite preserved visual acuity, and clinicians may be tempted to conclude that the ophthalmic risk has passed if the chart looks normal. This cohort argues against that shortcut. Symptoms, visual fields, and retinal nerve fiber layer measurements need to be interpreted together, because each reflects a different layer of disease activity.
Tertiary referral patterns likely concentrated the sickest survivors
The cohort came from a specialized intracranial hypertension clinic, and that setting shapes interpretation. Referral centers attract patients with lingering symptoms, unresolved diagnostic questions, and more complicated courses than the average person recovering from CVT. A tertiary sample is useful precisely because it reveals what can happen when intracranial hypertension does not resolve cleanly, but it is not a prevalence survey of the entire CVT population.
That limitation does not weaken the signal; it narrows the claim. The study does not say that most patients with CVT will develop severe field loss or chronic headache. It does show that objective deficits can persist for years in a clinic-based CVT population even when visual acuity is largely intact and venous recanalization is common. For neurologists and neuro-ophthalmologists, the lesson is to keep looking beyond the acuity chart and beyond the first post-thrombotic visit.
Routine neuro-ophthalmic surveillance is the most defensible response
The combination of preserved acuity, frequent field loss, and lasting headache supports routine follow-up with automated perimetry and optical coherence tomography in CVT-related intracranial hypertension. Those tests are not redundant. Visual fields detect functional loss, while retinal nerve fiber layer thinning records structural injury that may persist even when symptoms fluctuate. Together, they provide a clearer view of whether the optic nerves are stabilizing or continuing to deteriorate.
For patients, the implication is straightforward and concrete: normal reading vision is not enough reassurance after CVT if intracranial pressure was elevated. For clinicians, the management burden is to monitor for subtle deterioration before it becomes permanent, and to recognize when headache has become a separate chronic problem rather than a direct proxy for active venous disease.
Longitudinal data from a larger and more representative CVT population would help define how often these deficits occur outside referral care and whether specific venous patterns predict later ophthalmic injury. For now, this cohort provides a cautionary clinical picture: after CVT, the eye exam can look stable while the visual field silently worsens, and the headache may keep going long after the thrombosis has receded.